| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50 - 1/250 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD246; NBLST3 |
| Entrez GeneID | 238 |
| clone | 7A11A4 |
| WB Predicted band size | 176kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ALK (AA: 1366-1468) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与ALK抗体相关的重要文献摘要：
1. **《Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer》**
- 作者：Soda M, et al.
- 摘要：该研究首次报道了EML4-ALK融合基因在非小细胞肺癌(NSCLC)中的致癌作用，揭示了ALK蛋白异常激活导致肿瘤发生，为后续ALK靶向治疗奠定基础。
2. **《Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer》**
- 作者：Kwak EL, et al.
- 摘要：研究验证了ALK抑制剂克唑替尼(Crizotinib)在ALK阳性NSCLC患者中的显著临床疗效，强调了ALK抗体检测作为患者分层治疗标志物的必要性。
3. **《KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer》**
- 作者：Takeuchi K, et al.
- 摘要：开发了一种基于免疫组化(IHC)的ALK融合蛋白检测方法，证实其在肺癌组织中的高灵敏度和特异性，推动ALK抗体在临床诊断中的应用。
4. **《ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma》**
- 作者：Bresler SC, et al.
- 摘要：探讨ALK基因突变在神经母细胞瘤中的功能异质性，发现不同突变对ALK抗体靶向治疗反应的影响，为个体化治疗提供依据。
这些文献覆盖了ALK抗体的基础机制、诊断方法和治疗应用，适用于肿瘤学及分子病理学研究参考。
ALK (Anaplastic Lymphoma Kinase) antibodies are essential tools in diagnostic pathology and cancer research, primarily targeting the ALK protein encoded by the *ALK* gene. Originally identified in 1994 through its involvement in chromosomal rearrangements associated with anaplastic large cell lymphoma (ALCL), ALK gained broader significance when fusion proteins (e.g., EML4-ALK) were linked to oncogenesis in non-small cell lung cancer (NSCLC), neuroblastoma, and other malignancies. These genetic alterations result in constitutive activation of ALK tyrosine kinase, driving uncontrolled cell proliferation and survival.
ALK antibodies are widely used in immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect ALK overexpression or fusion proteins, aiding in diagnosis and therapeutic decision-making. For example, ALK-positive NSCLC patients often benefit from ALK inhibitors like crizotinib. Common clones, such as D5F3 and ALK1. are validated for clinical assays, with some approved as companion diagnostics.
Beyond diagnostics, ALK antibodies serve research roles in studying signaling pathways, drug resistance mechanisms, and tumor biology. Their specificity and reliability are critical for identifying ALK-driven cancers, predicting treatment responses, and assessing prognosis. Despite advancements, challenges remain in standardizing detection methods and interpreting heterogeneous expression patterns. Overall, ALK antibodies are pivotal in advancing precision oncology and improving outcomes for patients with ALK-associated malignancies.
×
